{"url_path":"/sec/kpti/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1503802/0001193125-26-222808-index.html","accession_number":"0001193125-26-222808","cik":"0001503802","ticker":"KPTI","issuer_name":"Karyopharm Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1503802/0001193125-26-222808-index.html","primary_entity_key":"0001503802","primary_entity_name":"Karyopharm Therapeutics Inc."},"word_count":100,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed:\n\n \n\nExhibit\n\nNo.\n\nDescription\n\n99.1\n\n[Press Release issued by Karyopharm Therapeutics Inc. on May 14, 2026](kpti-ex99_1.htm)\n\n \n\n \n\n \n\n104\n\nCover Page Interactive Data File (formatted as Inline XBRL)\n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nKARYOPHARM THERAPEUTICS INC.\n\n \n\n \n\n \n\n \n\nDate: May 14, 2026\n\n \n\n \n\n \n\nBy:\n\n \n\n/s/ Michael Mano\n\n \n\n \n\n \n\n \n\n \n\n \n\nMichael Mano\n\n \n\n \n\n \n\n \n\n \n\n \n\nExecutive Vice President, Chief Legal Officer and Secretary"}